BIES.F Stock Overview
Develops, manufactures, and sells biological and biotechnological pharmaceutical products in Germany and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Biotest Aktiengesellschaft Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €30.48 |
| 52 Week High | €35.92 |
| 52 Week Low | €28.78 |
| Beta | 0.22 |
| 11 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | 21.82% |
| Change since IPO | -36.50% |
Recent News & Updates
Recent updates
Shareholder Returns
| BIES.F | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | 1.0% | -0.2% |
| 1Y | n/a | 10.7% | 22.9% |
Return vs Industry: Insufficient data to determine how BIES.F performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how BIES.F performed against the US Market.
Price Volatility
| BIES.F volatility | |
|---|---|
| BIES.F Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 10.3% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in US Market | 15.3% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: BIES.F has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine BIES.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1946 | 2,426 | Peter Janssen | www.biotest.com |
Biotest Aktiengesellschaft develops, manufactures, and sells biological and biotechnological pharmaceutical products in Germany and internationally. It operates through three segments: European Union, Rest of the World, and Stateless. The company specializes primarily in the therapeutic areas of clinical immunology, haematology, and intensive care medicine.
Biotest Aktiengesellschaft Fundamentals Summary
| BIES.F fundamental statistics | |
|---|---|
| Market cap | US$1.43b |
| Earnings (TTM) | US$189.93m |
| Revenue (TTM) | US$840.24m |
5.9x
P/E Ratio1.3x
P/S RatioIs BIES.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BIES.F income statement (TTM) | |
|---|---|
| Revenue | €782.60m |
| Cost of Revenue | €436.40m |
| Gross Profit | €346.20m |
| Other Expenses | €169.30m |
| Earnings | €176.90m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Jul 30, 2024
| Earnings per share (EPS) | 4.47 |
| Gross Margin | 44.24% |
| Net Profit Margin | 22.60% |
| Debt/Equity Ratio | 131.3% |
How did BIES.F perform over the long term?
See historical performance and comparison